





<p>Shots of blood draw</p> <p>FILE from Kite Pharma - cells being processed</p>	<p>JAGLOWSKI (jag-LAU-skee), WHO WAS LEADING A TRIAL AT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER - JAMES CANCER HOSPITAL AND SOLOVE RESEARCH INSTITUTE ON A GROUNDBREAKING THERAPY KNOWN AS CAR-T.</p> <p>THE TREATMENT USES A PATIENT’S OWN WHITE BLOOD CELLS THAT ARE RE-TRAINED IN A LABORATORY TO RECOGNIZE MARKERS ON THE SURFACE OF CANCER CELLS THEN ATTACKS AND KILLS ONLY THOSE CELLS. :20</p>
<p><b>CG: Samantha Jaglowski, MD, MPH</b> The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute</p>	<p><i>“It’s a patient’s own cells that are reinfused and go to work. This is, you know, really kind of the epitome of personalized medicine.” :08</i></p>
<p>Shots of Robyn in CT scan</p> <p>Shots of techs looking at Robyn’s scans</p>	<p>ROBYN FLEW FROM HER HOME IN CHARLOTTE, NORTH CAROLINA, TO COLUMBUS, OHIO, TO BE PART OF THE TRIAL, AND THREE MONTHS AFTER RECEIVING HER CAR-T CELL INFUSION, SHE WAS IN REMISSION. :08</p>
<p><b>Dr. Jaglowski (CG’d earlier)</b></p>	<p><i>“And this is the exciting thing, patients who are still in remission at six months after the therapy don’t tend to relapse. So there are people out there who have gotten this therapy seven years ago who remained in remission.” :12</i></p>
<p>FILE from Kite Pharma - cells being reinfused</p>	<p>THE INFUSION ONLY TAKES A FEW MINUTES, BUT HAS LASTING RESULTS. IN FACT, NEARLY SIXTY PERCENT OF PATIENTS RESPOND TO THE TREATMENT WITHIN THE FIRST FEW DAYS.</p>
<p>Shots of Steve working on car at home</p>	<p>SOMETHING STEVE FULKERT (FALL-kert) EXPERIENCED FIRST HAND. AFTER SEVERAL ROUNDS OF CHEMO FAILED TO CONTROL HIS LYMPHOMA, HE RECOGNIZED RIGHT AWAY THAT CAR-T WAS WORKING FOR HIM. :16</p>
<p><b>CG: Steve Fulkert</b> <b>Received CAR-T therapy</b></p>	<p><i>“Each day I would anxiously measure my throat and it, you know, it would get smaller and the pain would diminish, and after six days they let me out, and I was able to go back to work, I think, on day eight.” :14</i></p>
<p>Shots of Steve working on car</p> <p>Shots of Dr. Jaglowski working</p> <p>Shots of Robyn in CT scan</p>	<p>A FEW MONTHS LATER, STEVE LEARNED THERE WAS NO SIGN OF CANCER ANYWHERE IN HIS BODY. SOMETHING EXPERTS SAY IS INSPIRING HOPE FOR THE FUTURE OF CANCER CARE.</p> <p>AT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER - JAMES</p>

**Producers and Reporters: To download scripts, video and photos go to:**  
<http://www.multimedianeewsroom.tv>

<p>Shot of Steve closing hood of car and walking away.</p> <p><b>(PACKAGE END) -----</b></p> <p><b>ANCHOR TAG</b></p>	<p>CANCER HOSPITAL AND SOLOVE RESEARCH INSTITUTE THIS IS BARB CONSIGLIO REPORTING. :15</p> <hr/> <p>CAR-T WAS FIRST APPROVED BY THE F-D-A IN JULY TO TREAT A RARE FORM OF LEUKEMIA IN CHILDREN.</p> <p>BUT THE NEWLY-APPROVED CAR-T TREATMENT IN ADULTS TARGETS A CANCER THAT AFFECTS THOUSANDS OF PEOPLE EACH YEAR.</p> <p>ONGOING RESEARCH IS ALSO TESTING CAR-T TREATMENT IN DISEASES SUCH AS BREAST CANCER, LUNG CANCER AND SARCOMA.</p>
---	--

### SOCIAL MEDIA

<p> <b>Share it! Suggested tweet:</b></p> <p> <b>Suggested post:</b></p>	<p>FDA approves breakthrough CAR-T therapy that is putting cancer patients with limited treatment options into remission: <a href="http://bit.ly/2hIYmLE">bit.ly/2hIYmLE</a></p> <hr/> <p>The FDA has approved the use of the breakthrough cancer therapy known as CAR-T for an aggressive type of lymphoma. Many patients who haven't responded to traditional cancer therapies are in remission within a few months of receiving this "living drug" that uses their own cells to attack and kill the cancer: <a href="http://bit.ly/2hIYmLE">bit.ly/2hIYmLE</a></p>
---	---

### EXTRA BITES

<p><b>CG: Samantha Jaglowski, MD, MPH</b> The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute</p>	<p>Dr. Jaglowski describes how T-cells are "retrained:" : <i>"It trains them to recognize a marker on the surface of cancer cells, and depending on what the cancer is, we can train them to recognize different markers. And then we can re-infuse those cells into patients."</i></p> <p>Dr. Jaglowski compares normal survival rates to CAR-T results: <i>"We know that the response rate to the next line of therapy in these patients is about 26 percent with a median overall survival of a little over six months, so these are patients who have bad lymphoma. In this study, the overall response rate is close to 60 percent and the median overall survival hasn't yet been reached."</i></p> <p>Dr. Jaglowski talks about Robyn's reaction to CAR-T therapy: <i>"Roughly five months after we collected her cells, we were able to get her infused, and it was cool because you could feel the lymph nodes going down within days of her getting the infusion. About a month later, she couldn't feel them at all."</i></p> <hr/>
--	--


**Producers and Reporters: To download scripts, video and photos go to:**  
<http://www.multimedianeewsroom.tv>

<p><b>CG: Robyn Stacy-Humphries</b> Lymphoma patient</p>	<p>Robyn describes how quickly CAR-T therapy worked for her: <i>“The amazing thing was the lymph nodes that I could feel, which at that time were in my left neck, left armpit and right groin, started melting. They had decreased in volume within 24 hours, and within five to seven days they were completely gone on physical exam.”</i></p> <p>Robyn says she believes CAR-T is the future of cancer care: <i>“I just think it’s going to change everything, and it’s, what they’re talking about is the personalized cancer therapy, where somebody can look at a certain cancer and treat somebody with less toxicity as compared to the traditional agents.”</i></p>
<p><b>CG: Steve Fulkert</b> Received CAR-T therapy</p>	<p>Steve says CAR-T gives hope to patients without other options: <i>“They want to get this treatment to market as fast as possible so that they can hopefully improve the chances for people who have very few good options remaining.”</i></p> <p>Steve says 3 months after his infusion, his scans were clear: <i>“They came back clear, so in a matter of three months, I had been put into remission.”</i></p>

**For viewer information on this story contact:**

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital  
and Richard J. Solove Research Institute  
The James Line: 1-800-293-5066  
Log onto <http://www.cancer.osu.edu> - click on “Media Room”

Produced by:

**MEDIA  SOURCE**

1800 West 5th Ave.  
Columbus, Ohio 43212  
Phone: (614) 932-9950 Fax: (614) 932-9920  
[www.mediasourcetv.com](http://www.mediasourcetv.com)

**The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer  
Hospital and Richard J. Solove Research Institute  
Media Relations Department: (614) 293-3737**

**Producers and Reporters: To download scripts, video and photos go to:**  
<http://www.multimedianeewsroom.tv>